BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Neural Therapeutics Commences Trading on Frankfurt Stock Exchange

  March 31, 2025

   · 

  5 min read
• Press Releases

  Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

  Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear Implant

  March 31, 2025

   · 

  15 min read
• 

  Diabetes

  Vertex Cuts Diabetes Asset, but Analysts Keen on Phase III Option

  Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge loss for Vertex given that the company has a more advanced type 1 diabetes candidate in zimislecel.

  March 31, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• Press Releases

  Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

  March 31, 2025

   · 

  12 min read
• Press Releases

  WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial

  March 31, 2025

   · 

  12 min read
• Press Releases

  Late-Breaking Clinical Trial Presented at the American College of Cardiology Supports Low-Dose Colchicine, 0.5 mg to Treat Cardiovascular Disease by Reducing Progression of Coronary Plaque

  March 31, 2025

   · 

  6 min read
• Press Releases

  TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

  March 31, 2025

   · 

  17 min read
• Press Releases

  Radiance Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of RB-164™, an ROR-1 Targeted ADC, for Hematologic and Solid Malignancies

  March 31, 2025

   · 

  2 min read
• Press Releases

  GenomOncology Partners with Chronetyx Laboratories to Accelerate Cancer Care Through Comprehensive Genomic Profiling

  March 31, 2025

   · 

  3 min read
• Press Releases

  MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies

  March 31, 2025

   · 

  5 min read